Curcuma longa and Boswellia serrata Extracts Modulate Different and Complementary Pathways on Human Chondrocytes In Vitro: Deciphering of a Transcriptomic Study

Christelle Sanchez1,2*, Jérémie Zappia1,2, Cécile Lambert1,2, Jacques Foguenne3, Yvan Dierckxsens4, Jean-Emile Dubuc1,5, Jean-Pierre Delcour6, André Gothot3 and Yves Henrotin1,2,7

1MusculoSkeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, University of Liège, Liège, Belgium, 2Center for Interdisciplinary Research on Medicines, University of Liège, Liège, Belgium, 3Department of Laboratory Hematology, Liège University Hospital, Liège, Belgium, 4Tilman SA, Ballonville, Belgium, 5Cliniques Universitaires de St Luc, Brussels, Belgium, 6Centre Hospitalier Du Bois de L’Abbaye, Seraing, Belgium, 7Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium

Objectives: Curcuma longa (CL) and Boswellia serrata (BS) extracts are used to relieve osteoarthritis symptoms. The aim of this in vitro study was to investigate their mechanisms of action at therapeutic plasmatic concentrations on primary human osteoarthritic (OA) chondrocytes.

Methods: BS (10–50 μg/ml) and CL (0.4–2 μg/ml corresponding to 1–5 µM of curcumin) were evaluated separately or in combination on primary chondrocytes isolated from 17 OA patients and cultured in alginate beads. Ten patients were used for RNA-sequencing analysis. Proteomic confirmation was performed either by immunoassays in the culture supernatant or by flow cytometry for cell surface markers after 72 h of treatment.

Results: Significant gene expression modifications were already observed after 6 h of treatment at the highest dose of CL (2 μg/ml) while BS was significantly effective only after 24 h of treatment irrespective of the concentration tested. The most over-expressed genes by CL were anti-oxidative, detoxifying, and cytoprotective genes involved in the Nrf2 pathway. Down-regulated genes were principally pro-inflammatory cytokines and chemokines. Inversely, BS anti-oxidant/detoxifying activities were related to the activation of Nrf1 and PPARα pathways. BS anti-inflammatory effects were associated with the increase in GDF15, decrease in cholesterol cell intake and fatty acid metabolism-involved genes, and down-regulation of Toll-like receptors (TLRs) activation. Similar to CL, BS down-regulated ADAMTS1, 5, and MMP3, 13 genes expression. The combination of

Abbreviations: ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; FDR, false discovery rate; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IL, interleukin; MMP, matrix metalloproteinase; NGS, next-generation sequencing; OA, osteoarthritis; padj, p-value adjusted; RIN, RNA integrity number; RNA, ribonucleic acid; ROS, reactive oxygen species; SD, standard deviation; TKR, total knee replacement; TLR, Toll-like receptor; TNF, tumor necrosis factor.
INTRODUCTION

Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide. It is a serious disorder primarily affecting weight-bearing joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses, including pro-inflammatory pathways of innate immunity (Mobasher et al., 2019). Natural extracts from *Curcuma longa* and *Boswellia serrata* are known for their anti-oxidative and anti-inflammatory properties and are used to relieve clinical symptoms of OA for many years (Bannuru et al., 2018; Henrotin et al., 2019). Curcumin is the principal curcuminoid extracted from the *C. longa* (turmeric) root and has revealed a broad spectrum of bioactivities, including anti-oxidant, anti-inflammatory, anti-tumor, and anti-viral activities. At the molecular level, this multitargeted agent has been shown to act through numerous cell signaling pathways: the PI3K/Akt-1/mTOR, the Ras/Raf/MEK/ERK, the GSK-3β, the p53, and via NF-κB, Akt, and Nrf2/ARE pathways (Kunnumakkara et al., 2017; Jiang et al., 2020; Li et al., 2020; Pauletto et al., 2020). Recently, it was shown to increase the nuclear expression levels and promote the biological effects of Nrf2 via the interaction with Cys151 in Keap1, which makes it a therapeutic candidate against a broad range of oxidative stress-related diseases (Rahban et al., 2020). Furthermore, curcumin inhibits lipo-oxygenase (LOX) and cyclooxygenase (COX), xanthine oxidase activities, nitric oxide synthesis, ROS generation, and pro-inflammatory cytokines and chemokines release (Mathy-Hartert et al., 2009; Comblain et al., 2015; Comblain et al., 2016; Rahban et al., 2020; Mohan et al., 2021). Boswellic acids, a class of triterpenes, are the bioactive constituents of *B. serrata* extracts. In the resin, more than 12 different boswellic acids have been identified. Their anti-inflammatory actions are caused by different mechanisms of action. They include inhibition of leukotriene, and to a less extent prostaglandin synthesis, inhibition of the complement system at the level of conversion of C3 into C3a and C3b, the decreased production of proinflammatory cytokines including IL-1, IL-2, IL-6, IFN-γ, and TNF-α, inhibition of formation of oxygen radicals and lysosomal enzymes, and the suppression of the proteolytic activity of cathepsin G and elastase (Tausch et al., 2009; Ammon 2016).

Both CL and BS was significantly more effective than CL or BS alone on many genes such as IL-6, CCL2, ADAMTS1, and 5.

**Conclusion:** BS and CL have anti-oxidative, anti-inflammatory, and anti-catabolic activities, suggesting a protective effect of these extracts on cartilage. Even if they share some mechanism of action, the two extracts act mainly on distinct pathways, and with different time courses, justifying their association to treat osteoarthritis.

**Keywords:** osteoarthritis, transcriptomic (RNA-seq), *Curcuma*, *Boswellia*, chondrocyte

MATERIAL AND METHODS

Ethical Statement

Articular cartilage samples from 17 successive patients with knee OA were obtained at the time of total knee joint replacement (TKR) surgery. All participants have signed the informed patient consent, and the protocol was approved by the ethical committee of the University of Liège (B70720108313). All procedures followed the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, revised in 2000. **Supplementary File S1** gives an overview of the patients’ characteristics and their use in this study.

Study Medication

*Curcuma longa* extract (CL, containing 89.6% of curcumin and 9.1% of demethoxycurcumin) and *B. serrata* oleoresin (BS, containing 2.83% 3-acetyl-11-keto-β-boswellic acid, 4.35% 11-keto-β-boswellic acid, 10.17% α-boswellic acid, 15.5% β-boswellic acid, 2.24% acetyl α-boswellic acid, and 6.63% acetyl-β-boswellic acid) were used. These extracts were provided by Tilman SA (Belgium) and stored at ambient temperature, protected from light. Before use, the extracts were solubilized in tetrahydrofuran at 4 mg/ml (CL) or 100 mg/ml (BS). They...
were further diluted in tetrahydrofuran to achieve a final 0.1% of solvent in each culture condition. We evaluated two concentrations for each extract, corresponding to the minimal and the maximal concentrations of the active compounds found in the plasma after oral treatment with these extracts (Buchele and Simmet 2003; Henrotin et al., 2013).

**Study Design**

**Supplementary File S2** gives a detailed overview of the study design. In short, for transcriptome analysis, chondrocytes were untreated (control) or treated with CL at 0.4 or 2 μg/ml, BS at 10 or 50 μg/ml, or a combination of CL and BS (CL/BS) at low or high concentration during 6 and 24 h. For protein analysis, chondrocyte supernatant was used to quantify IL-6, CCL2, NO2, and GDF15 using specific immunoassays or Griess reaction and standardized according to each culture well DNA content on each culture condition performed in triplicate. Flow cytometry was performed on five other chondrocyte cultures to evaluate the presence of TLR1-2-4-6 on the cell surface.

**Chondrocyte Alginate Beads Culture**

Full-depth articular cartilage was excised, chondrocytes were enzymatically isolated and suspended in alginate beads at 4 million cells per ml as previously described (Sanchez et al., 2021), and cultured for 3 days in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 10 mM HEPES, penicillin (100 U/ml) and streptomycin (100 μg/ml), 200 μg/ml glutamine, 50 μg/ml ascorbic acid, and 2 mM proline (all were obtained from Biowest, France, except for ascorbic acid and proline, which were from Sigma-Aldrich, Germany). Alginate beads containing chondrocytes were placed in 24-well plates, nine beads per well. Three wells were used per time point and treatment. After the first 3 days, the culture media were replaced by a fresh one with the same composition but containing CL, BS, CL/BS, or tetrahydrofuran 0.1% alone for untreated control as described in the study design. For transcriptomic analysis, after 6 and 24 h of treatment, alginate beads were transferred to cold 0.1 M citrate for dissolution and, after centrifugation, cells were homogenized in lysis buffer for ribonucleic acid extraction, and then stored frozen at −80°C until RNA extraction (Qiagen, Netherlands).

After 72 h, cell cultures were stopped, and supernatants were collected and stored at −20°C for further analysis. For protein content measurement by immunoassays, cells were homogenized in 1 ml of Tris-HCl buffer by ultrasonic dissociation for 20 s at 4°C to measure total DNA content.

**Flow Cytometry**

All reagents used for the flow cytometry were purchased from BD Biosciences (France) unless indicated otherwise. Alginate beads from two wells were pooled and dissolved in 2 ml 0.1 M citrate containing 1 μl LIVE/DEAD green stain kit (Invitrogen, United States) at 4°C and protected from light. After 25 min incubation, chondrocytes were centrifuged 5 min at 1200 rpm, rinsed in 1 ml NaCl 0.9 g/L at 4°C, centrifuged for 5 min at 1200 rpm, and suspended in 300 μl NaCl 0.9 g/L. One hundred microliters of cell suspension was transferred to polypropylene tubes and incubated with 5 μl of FcBlock for 10 min at room temperature to block any unspecific binding. Then, 50 μl of Brilliant stain buffer and 5 μl of each specific antibody were added. Antibodies used were mouse IgG anti-human TLR1 (BV421-conjugated, 566430), TLR2 (Alexa fluo 647-conjugated, 558319), TLR4 (BB700-conjugated, 745946), and TLR6 (PE-conjugated, 566339). For each sample and each treatment, one tube with all control isotypes and one other tube with no antibody were also performed in parallel to measure the non-specific binding and autofluorescence of the cells. After 20 min of incubation at room temperature and protection from light, cells were washed and suspended in 400 μl (in BD lyse wash assistant) before being read for fluorescence in flow cytometry (BD FACS Canto II). A total of 3000 to 5000 living cells (following LIVE/DEAD staining in 488 nm) were analyzed per sample. The difference between the median fluorescence and the median autofluorescence in each channel was calculated for each sample to obtain the median fluorescence intensity. A cut-off placed at the end of the autofluorescence peak was also used to estimate the percentage of highly positive cells in each sample.

**DNA and NO2 Quantification**

DNA content of cell culture was measured according to a fluorometric method (Labarca and Paigen 1980). Nitric oxide (NO) production was determined by quantifying its derived product, nitrite, in the culture supernatant using a spectrophotometric method based on the Griess reaction (Green et al., 1982).

**RNA Extraction**

Total RNA was extracted using an RNeasy mini kit (Qiagen, Netherlands) according to the instructions of the manufacturer. The yield of the extracted RNA was determined spectrophotometrically by measuring the optical density at 260 nm. The purity and quality of extracted RNA were further evaluated using an RNA Nano 6000 Bioanalyzer Agilent (Santa Clara, United States) according to the manufacturer’s instructions. High-quality RNAs with RNA quality indicator scores (RIN) of >8 were used.

**RNA-Seq and Differential Gene Expression Analysis**

One hundred nanograms of RNA from each culture condition was used for this analysis. Libraries were prepared with the Illumina Truseq stranded mRNA sample prep kit according to the manufacturer’s instructions. Poly(A) plus RNA was enriched using oligo(dT) beads followed by fragmentation and reverse transcription. Afterward, the 5’ and 3’ ends of cDNA fragments were prepared to ensure efficient ligation of “Y” adapters containing unique barcode and primer binding sites. Finally, ligated cDNAs were PCR amplified to be ready for cluster generation and sequencing.

Sequencing was performed on Novaseq (Illumina), paired-end reads (150-10-10-150), and NovaSeq S4 V1.5 300 cycles XP workflow, generating around 20 M reads per sample.
Denaturated NGS library fragments were flowed across a flow cell and hybridized on a lawn of complementary Illumina adapter oligos. Complementary fragments were extended, amplified via bridge amplification PCR, and denatured, resulting in clusters of identical single-stranded library fragments. Fragments were primed and sequenced utilizing reversible terminator nucleotides. Base pairs were identified after laser excitation and fluorescence detection.

Raw data were demultiplexed into individual libraries. After filtering out reads mapping to rRNA, tRNA, mitochondrial RNA, and other contaminants (e.g., adapters, etc.) using bowtie2, reads were aligned onto the human reference genome (GRCh38 and Ensembl 105 annotation) and quantified with Star to give the Counts file. Quality control of sequencing reads was assessed with FASTQC and quality control after mapping with Picard tools. Compilation of tool metrics was performed with MultiQC.

Differential expression analysis was made in R (version 4.1.2, https://www.R-project.org/) using the DESeq2 package (1.34.0) (Love et al., 2014), biomaRt package (version 2.50.1) (Durinck et al., 2009), and R code design = ~ Patient + Treatment. Analysis was performed with treatment as a contrast: each treated vs. control and the combination vs. each extract separately. Volcano plots and Venn diagrams were generated using ggplot2 (version 3.5) and nVennR (version 0.2.3) (Perez-Silva et al., 2018). Gene set enrichment analysis (GSEA) was performed using clusterProfiler package (4.2.0) (Wu et al., 2021), rWikipathways (1.14.0) (Slenter et al., 2018), and visualized on KEGG diagrams with pathview (1.34.0, considering only DEGs with padj <0.01) (Luo and Brouwer 2013).

A false discovery rate (FDR) of 0.01 was used to assess the statistical significance.

ELISA for IL-6, CCL2, and GDF15

Protein amount of IL-6, CCL2, and GDF15 was measured from the supernatant, by specific enzyme-amplified sensitivity immunoassays (IL-6: Invitrogen cytoset CHC1263; CCL2: R&Dsystems UK DuoSet DY279; GDF15: R&Dsystems UK DuoSet DY957). Protein content was normalized to the DNA content.

Statistical Analysis

For the transcriptome analysis, the DESeq2 Bioconductor package was used for normalization, principal component analysis (PCA), and differential gene expression. DESeq2 differential gene analysis was based on the hypothesis that most genes were not differentially expressed (Anders and Huber 2010; Love et al., 2014). The method was based on the negative binomial distribution model. Within the DESeq2 package, and with the estimate SizeFactorsForMatrix function, scaling factors were calculated for each run. After dividing gene counts by each scaling factor, DESeq2 values were calculated as the total of rescaled gene counts of all runs.

The amplitude of changes is represented either in the log2Foldchange format (classical representation from DESeq2, where “0” means “no change,” “1” means “2-fold induction,” and “−1” means “2-fold decrease”) or in fold change (where “1” means “no change,” “2” means “2-fold induction,” and “0.5” means “2-fold decrease”).

Along with the standard p-value, an adjusted p-value (padj) was calculated. The adjustment methods included the Bonferroni correction (“Bonferroni”) in which the p-values were multiplied by the number of comparisons. Less conservative corrections were also included by Holm (“holm”) (Holm 1979), Hochberg (“hochberg”) (Hochberg 1988), Hommel (“hommel”) (Hommel 1988), Benjamini & Hochberg (“BH” or its alias “fdr”) (Benjamini and Hochberg 1995), and Benjamini & Yekutieli (“BY”) (Benjamini and Yekutieli 2001), respectively. The “BH” (aka “FDR”) and “BY” methods of Benjamini, Hochberg, and Yekutieli control the false discovery rate, i.e., the expected proportion of false discoveries among the rejected hypotheses.

To avoid any confusion coming from a threshold effect on padj and log2FC, we compared gene by gene the log2FC at different times and treatments for each patient using ANOVA and Bonferroni post-test to detect significant accentuations between the two conditions (Supplementary Files S4, S9).

For the protein analyses, results were statistically analyzed using GraphPad Prism 6.0. The mean is calculated for the triplicate of each cell culture (n = 12) or delta of median fluorescence and median autofluorescence for flow cytometry (n = 5). These values will be first analyzed in GraphPad Prism 6.0 to check their normality (D’Agostino & Pearson omnibus test). Then, paired one-way ANOVA was used to compare each treatment to the control, with multiple-comparison correction (Holm–Sidak’s) or Friedman test for repeated measures with Dunn’s post-test, to calculate the statistical significance.

RESULTS

Global RNA-Seq Analysis of Differentially Expressed Genes (DEGs)

After 6 h of treatment, 3 DEGs were observed with CL 0.4 μg/ml, 1932 with CL 2 μg/ml, 13 with BS 10 μg/ml, and 8 with BS 50 μg/ml in OA chondrocytes compared to the untreated control, respectively, with a padj <0.01 and a Log2FoldChange >0.32 corresponding to a fold change of at least or >33% more or >25% less (Figure 1 and Supplementary File S3).

After 24 h of treatment, CL at 2 μg/ml and BS at 50 μg/ml significantly modified the expression of 3534 and 1116 genes as shown on volcano plots in Figure 1. Only one gene was significantly modulated by CL at 0.4 μg/ml (Supplementary File S4). Using DESeq2, no significant DEG was found between both BS concentrations. Padj of the DEGs w lower at 50 compared to 10 μg/ml but log2FC was not modified (Figures 1B,D). Complete DESeq2 analysis between treatments after 24 h is listed in Supplementary File S4. An ANOVA analysis showed that after 24 h of treatment, 161 DEGs were significantly more up- or down-regulated than after 6 h and that 47 genes switched from up- to down-regulation or inversely (Supplementary File S5).
Based on these preliminary data, only 24 h treatment with CL 2 μg/ml and BS 50 μg/ml or the combination of CL 2 μg/ml and BS 50 μg/ml have been further analyzed.

GSEA analysis on GO terms or wikiPathways for CL or BS is shown in Supplementary File S6, and the KEGG diagram in Supplementary File S7.
C. longa Effect on OA Chondrocyte Transcriptome

The most up-regulated genes with CL (HMOX1, NQO1, SQSTM1, FTH1, GCLM, TNC, TXNRD1, EPHX1, etc.) were anti-oxidant and cytoprotective genes belonging to the Nrf2 pathways (Supplementary File S8).

CL down-regulated 110 pro-inflammatory genes in GO ontology « inflammatory response GO:0006954 » (Supplementary File S8), including NFKB1, NFKB2, chemokines (CXCL6, CXCL1, CXCL8/IL-8, CCL2, etc.), cytokines (including TNFa, IL6, IL16, IL17R, and IL34), NOS2, and other pro-inflammatory genes (including FSTL1, POSTN, IGFBP4, and CHI3L1). CL also modulated the expression of several genes of the arachidonic acid metabolism. It decreased the two most expressed phospholipase A2 genes by human chondrocytes (PLA2G2A and PLA2G4A), but also PTGS1 and PTGS2 (also known as COX-1 and COX-2), as well as PTGES and PTGES2. In contrast, CL increased PTGS3. CL decreased several prostanoid receptors including PGE2 (PTGER4 and to a lesser extent PTGER2), PGF2α (PTGFR), and PGI2 (PTGIR) receptors (Supplementary File S4 and KEGG diagram in Supplementary File S7). CL also had important inhibitory effects on genes involved in cartilage catabolism like MMP13, MMP1, ADAMTS5, MMP3, and HTRA1. It highly up-regulated HTRA3 (5-fold increased) and down-regulated 126 genes involved in cartilage development and endochondral ossification (ACAN, COL2A1, COMP, TGM2, F13A1, IBSP, GIIL, SPARC, CCN2, GREM1, WNT5A, FGF1, VEGFA, VEGFB, VEGFC, etc.) (Supplementary File S8).

B. serrata Effect on OA Chondrocyte Transcriptome

The most BS up-regulated gene was GDF15 (2.4 log2fold change corresponding to a 5.3-fold increase). Many genes carrying one anti-oxidant response element (ARE) were also up-regulated by BS, such as HMOX1 and FTL, and metallothioneins which are a signature of Nrf1 activation (Supplementary File S8 and Figure 2). PPAR-α (PPARA, +12%) and PPAR-γ coactivator-1 alpha (PPARGC1A+46%, also known as PGC-1α), SIRT1, and SIRT2 were also up-regulated.

Many genes are involved in lipid cell intake and cholesterol biosynthesis, including the LDL receptor (LDLR), HMG-CoA reductase (HMGCGR), HSD17B7, FDX1, SQLE, LSS, CYP51A1, DHCR7, DHCR24, and SREBF2 were significantly down-regulated by BS.

BS regulated a lot of genes involved in inflammation. IL6, CCL2, FSTL1, IL16, IL17 receptors, MyD88, TLR1, TLR4, and TLR6 were down-regulated while HMBG2, NRROS, CYP26B1, and TOLLIP were up-regulated (See Supplementary File S9 for details). Note that both IL36 and its antagonist IL36RN were up-regulated.

BS significantly up-regulated the autophagy pathways (GO BP 0006914 and related). Autophagy inducer genes like FOXO1, LAMP2, RUBCNL, SQSTM1, and PLEKHM1 were up-regulated (Supplementary File S9 and Table 5).

Finally, BS down-regulated some important catabolic enzymes like ADAMTS1 and 5, MMP3, and MMP13 but also a panel of 57 genes involved in cartilage development and endochondral ossification (including 16 of the 34 collagen genes expressed, and
FIGURE 3 | Volcano plots and Venn diagrams of C. longa 2 μg/ml, B. serrata 50 μg/ml, and the combination after 24 h treatment on OA chondrocytes. Threshold $p_{adj} < 0.01$ and Log2FoldChange $>|0.32|$, $n = 10$. 
most genes involved in chondrocyte hypertrophy like FGF1, POSTN, COL10A1, ASPN, IBSP, and BMP5) (Supplementary File S9). The global B. serrata’s main activities are schematized in Figure 2.

Distinct and Common Pathways by C. longa and B. serrata Extract

From the 3534 DEGs by CL 2 μg/ml, 534 were also modified by 50 μg/ml BS. From these, 152 up-regulated and 264 down-regulated were common, and 118 were regulated in an opposite way (Figure 3).

The CL and BS DEGs were individually analyzed to identify those which were preferentially regulated by CL 2 μg/ml or BS 50 μg/ml. Using ANOVA and Bonferroni post-test, we compared gene by gene, and for each patient, the log2FC. We found that 591 genes were similarly modified by the two extracts (“similar”), 104 genes were significantly more affected by BS than CL (“BS50 driven”), and 377 genes were more regulated by CL than BS treatment (“CL2 driven,” Supplementary File S9). When comparing the DESeq2 between the combination CL2/BS50 with those of CL2 or BS50, we showed that the combination was statistically more efficient (p < 0.05) on 258 genes than CL 2 μg/ml alone, 629 genes than BS 50 μg/ml alone, and 125 genes than both CL 2 μg/ml and BS 50 μg/ml (Supplementary File S10).

Distinct anti-oxidative and detoxifying pathways activation by C. longa and B. serrata on OA chondrocytes.

Inversely, the two extracts were antagonists of some transcription factors involved in Nrf pathways. C. longa activated Nrf2 and B. serrata Nrf1 pathway, both involving common small MAFs (Figure 4).

The combination of CL with BS did not modify the effect of CL on genes related to Nrf2. Metallothioneins which are Nrf1-specific genes were strongly down-regulated by CL (−0.35 to −1.46 log2FC) but up-regulated in the presence of BS. MT1X was the only metallothionein gene up-regulated by BS in the presence of CL but was less differentially expressed by chondrocytes in the presence of CL (0.69 vs. 1.21 log2FC with BS alone). The up-regulation of BS on PPARGC1A fully disappeared in the presence of CL.

Tables 1, 2 summarize the comparative anti-inflammatory and anti-catabolic activities of CL and BS, highlighting some common and specific targets for the two extracts.

Proteomic Analysis

IL-6, CCL2, GDF15, and NO2 were quantified on 72 h treated chondrocyte supernatants (Figure 5). As for the gene expression at 24 h, CL and BS significantly decreased IL-6, CCL2, and NO2 but increased GDF15 protein release after 72 h. The combination was significantly more effective than CL or BS alone on all these proteins after 72 h, except no difference between CL and the combination for NO2 production (Figure 5).
Using flow cytometry, we compared the presence of the TLR1, TLR2, TLR4, and TLR6 at the chondrocyte surface after 72 h of treatment (Figure 6). CL decreased significantly TLR2 protein but did not affect TLR1, TLR4, and TLR6. BS significantly decreased all tested TLR receptors at the chondrocyte surface (Figure 6). No statistical difference
was observed among BS, CL, and the combination of both extracts.

DISCUSSION

In this study, we aimed to identify molecular pathways modulated by C. longa and/or B. serrata extracts in human OA chondrocytes. We used NGS technology to generate the transcriptome, capturing dynamic changes in chondrocytes induced by the treatment, compared to control or each extract independently.

For the most regulated genes, we extended our transcript analysis to the protein level by directly measuring proteins in culture supernatants with immunoassays or flow cytometry. We demonstrated that C. longa and B. serrata had different time-course effects on OA chondrocyte genes and acted on different but complementary pathways to induce anti-oxidative, detoxifying, anti-inflammatory, and anti-catabolism activities. These findings may explain some effects observed in the clinical studies with OA patients and justify the combined use of CL and BS (Sengupta et al., 2008; Haroyan et al., 2018; Henrotin et al., 2019; Wang et al., 2020) (Bannuru et al., 2018; Zeng et al., 2021).

It is well known that curcumin activates the Nrf2 pathways, and particularly induces HMOX1 gene expression (Balogun et al., 2003). More recently, it was demonstrated that curcumin interacts directly with Keap1 to activate Nrf2 pathways and induce anti-oxidant and cytoprotective genes expression (Rahban et al., 2020). In this study, we showed that in chondrocytes, C. longa induced transcription of genes involved in iron/heme homeostasis, detoxification of ROS (glutathione and thioredoxin metabolism), autophagy, and enhanced the redox potential via NADPH. B. serrata induced the same iron/heme homeostasis and autophagy genes but in addition induced metallothioneins, a family of cysteine-rich metal-binding proteins that are important for zinc and copper homeostasis, protection against oxidative stress, and buffering against toxic heavy metals.

C. longa-specific effects concern TNF inhibition, arachidonic acid metabolism to decreased prostanoids production and their receptors, and decrease in VEGFs and HTRA1 genes. In parallel to the decrease in TNF alpha gene expression, C. longa also decreased the expression of several TNF-induced protein genes (TNFAIP2, 3, 6, and 8, Supplementary File S4). These TNFAIPs have a positive role in the resolution of inflammation (Chen et al., 2020). The role of HTRA1, a serine protease, in joints has been recently reviewed (Tossetta et al., 2022). HTRA1 is involved in aggrecan, type II, VI collagens, and other matrix protein degradation as fibronectin (Chen et al., 2019). Its expression level is correlated with MMP13 and is increased in OA patients (Li et al., 2018). This is the first time that the inhibition of HTRA1 synthesis by CL is demonstrated. This new mechanism of action of CL supports clinical data demonstrating that CL reduced cartilage catabolism in OA (Henrotin et al., 2019).

The most particular effect of B. serrata was the inhibition of the inducible TLRs pathways, the fatty acid intake, and the intracellular cholesterol metabolism (HMG-CoA reductase-HMGCR and other enzymes involved in cholesterol synthesis). The action of BS on TLR is important since it was demonstrated that DAMPS released during cartilage extracellular matrix...
FIGURE 7 | Schematic overview of distinct action of *C. longa* and *B. serrata* on TLRs pathways. *B. serrata* decrease TLR1-4-6 and MyD88 gene expression after 24 h and TLR2 protein after 72 h, and also up-regulated TOLLIP gene expression, an inhibitor of TLRs, while *C. longa* only decreases TLR2 expression and protein. Both *C. longa* and *B. serrata* decreased downstream genes of the TLRs pathways like ADAMTS1, ADAMTS5, MMP-13, IL-6, and JAK2. As ADAMTS1 can degrade fibronectin, and fibronectin fragments could induce TLR4 activation, *C. longa* and *B. serrata* could attenuate this inflammation amplification loop.

FIGURE 8 | Benefits of using *B. serrata* in combination with *C. longa* for treating OA. The percentage is shown in comparison to *C. longa* alone. Genes in green and bold are DEGs specific to *B. serrata* treatment and unmodified with *C. longa* treatment.
degradation may stimulate chondrocytes to secrete more catabolic and inflammatory mediators by binding to TLR receptors (Lambert et al., 2020). BS reduced SREBF2 expression, a transcription factor induced by TLR4 and which induces LDLR and HMGCR expression (Dong et al., 2021). B. serrata increased PPARGC1A expression which is decreased in chondrocytes during OA and seems to be a key factor needed for adequate mitochondrial function and pro-inflammatory response to IL-1β (Wang et al., 2015). Therefore, reducing the TLR receptors is now presented as a therapeutic strategy to prevent cartilage degradation. All these pathways interact to control chondrolysis as illustrated in Figure 7. PPARGC1A expression is controlled by several signaling pathways including SIRT1, which is also up-regulated by B. serrata. Furthermore, PPARGC1A/NRF1 induces telomeres transcription, providing anti-senescence activity (Diman et al., 2016). B. serrata also induced HMGB2, a gene specifically inhibited in senescent cells (Guerrero and Gil 2016; Kim et al., 2018; Lawrence et al., 2018). This anti-senescence could contribute to prevent cartilage degradation in OA. Indeed, the chondrocyte senescence process was demonstrated to be an important feature in OA, related to the autophagy, oxidative, and inflammatory state of the cells (Rim et al., 2020).

With aging, the basic autophagic activity of cells decreases, following a down-regulated clearance efficiency. Subsequently, the aggregation of various macromolecular proteins increases, leading to eventual cell degeneration and functional defect, or even apoptosis (Duan et al., 2020). Recent studies have shown that the level of autophagy in OA cartilage is reduced (Feng et al., 2020), and that autophagy can protect chondrocytes from degradation (Carames et al., 2012). BS induces several genes promoting autophagy (FOXO1, RUBCNL, PLEKHM1, and SQSTM1), autophagy markers like ATG2A, and genes improving lysosomal functions like LAMP2, all of which would be beneficial in OA context (Kurakazu et al., 2019; Zhao et al., 2019; Ansari et al., 2021; Feng et al., 2022).

In this work, we attempted to use concentrations close to the plasmatic concentration achieved during oral treatment with C. longa and B. serrata extracts. But, due to the low bioavailability of curcumin, the efficacy could be greatly affected. This is for which C. longa extract needs to be optimized to increase curcumin bioavailability (Henrotin et al., 2013). However, most in vitro studies on curcumin effects use higher curcumin concentrations, usually ranging from 10 to 20 µM, even 50 µM. We observed that in addition to being unreachable in the clinic, curcumin concentrations of 10 µM and above are decreasing chondrocyte cell viability (personal communication). Concerning B. serrata extract, the extrapolation is further complicated by the different bioavailability of the six main boswellic acids supposed to be active. The more studied boswellic acid, acetyl 11-keto-β-boswellic acid, is less bioavailable (0.1 µM compared to 2.6 µM in the 50 µg/ml extract used) but others, also known to be very active like β-boswellic acid, are under-represented in our study (up to 30 µM in the plasma compared to 17 µM in the 50 µg/ml extract) (Buchele and Simmet 2003; Husch et al., 2013). Globally, we can estimate that our 10 to 50 µg/ml extract represents well the archived range of plasmatic concentrations during the oral treatment.

The main limitation of this study is the cartilage source. The cartilage came from patients with severe knee OA requiring joint replacement. In these patients, the cartilage was very damaged which did not represent all the osteoarthritis chondrocyte endotypes. Furthermore, a low number of OA cartilage samples were included in the flow cytometry experiment (n = 5). A larger number would maybe provide better statistical differences between the treatments.

In conclusion, in primary OA chondrocyte cultures, C. longa and B. serrata exert distinct and complementary anti-oxidative, anti-inflammatory, and anti-catabolic activities on OA articular chondrocytes (Figure 8). This in vitro study gives a rationale for their combined use in the therapeutic of OA.

DATA AVAILABILITY STATEMENT
The transcriptomic data analyzed for this study are deposited in Gene Expression Omnibus (GEO) repository, under accession number GSE201779 that are publicly accessible at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE201779. Other datasets presented in this study are included in the Supplementary Material.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the ethical committee of the University of Liège. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
CS, JZ, CL, JF, AG, and YH conceived and planned the experiments. CS carried out the experiments. J-ED and J-PD contributed to the article and approved the submitted version.

FUNDING
This study was funded by the Walloon region (Belgium) and Tilman SA.

ACKNOWLEDGMENTS
We would like to thank the staff of the GIGA ULiège Genomic Next Generation Sequencing platform for performing RNA sequencing.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.931914/full#supplementary-material
Love, M. I., Huber, W., and Anders, S. (2014). Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2. Genome Biol. 15, 530. doi:10.1186/s13059-014-0550-8

Luo, W., and Brouwer, C. (2013). Pathview: an R/Bioconductor Package for Pathway-Based Data Integration and Visualization. Bioinformatics 29, 1830–1831. doi:10.1093/bioinformatics/btt285

Mathy-Hartert, M., Jacquemond-Collet, I., Priem, F., Sanchez, C., Lambert, C., and Henrotin, Y. (2009). Curcumin Inhibits Pro-inflammatory Mediators and Metalloproteinase-3 Production by Chondrocytes. Inflamm. Res. 58, 899–908. doi:10.1007/s00011-009-0663-1

Mobasher, A., van Spil, W. E., Bidd, E., Uzieliene, I., Berntoiene, E., Bay-Jensen, A. C., et al. (2019). Molecular Taxonomy of Osteoarthritis for Patient Stratification, Disease Management and Drug Development: Biochemical Markers Associated with Emerging Clinical Phenotypes and Molecular Endotypes. Curr. Opin. Rheumatol. 31, 80–89. doi:10.1097/BOR.0000000000000567

Mohan, M., Hussain, M. A., Khan, F. A., and Anindya, R. (2021). Symmetrical and Un-symmetrical Curcumin Analogues as Selective COX-1 and COX-2 Inhibitor. Eur. J. Pharm. Sci. 160, 105743. doi:10.1016/j.ejps.2021.105743

Pauletto, M., Giantini, M., Tolosi, R., Basso, I., Barbarossa, A., Zaghini, A., et al. (2020). Curcumin Mitigates AFB1-Induced Hepatic Toxicity by Triggering Cattle Antioxidant and Anti-inflammatory Pathways. Antioxidants (Basel) 9. doi:10.3390/antiox9111059

Pérez-Silva, J. G., Araujo-Voces, M., and Quesada, V. (2018). nVenn: Generalized, Quasi-Proportional Venn and Euler Diagrams. Bioinformatics 34, 2322–2324. doi:10.1093/bioinformatics/bty109

Rahban, M., Habibi-Rezaei, M., Mazaheri, M., Saso, L., and Moosavi-Movahedi, A. A. (2020). Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications. Antioxidants (Basel) 9. doi:10.3390/antioxid9121228

Rim, Y. A., Nam, Y., and Ju, J. H. (2020). The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression. Int. J. Mol. Sci. 21. doi:10.3390/ijms21073258

Sanchez, C., Hemmer, K., Krömmelbein, N., Seilheimer, B., Dubuc, J. E., Antoine, C., et al. (2021). Reduction of Matrix Metalloproteinase 13 and Promotion of Chondrogenesis by Zell T in Primary Human Osteoarthritic Chondrocytes. Front. Pharmacol. 12, 635034. doi:10.3389/fphar.2021.635034

Sengupta, K., Aliri, K. V., Satish, A. R., Mishra, S., Golakoti, T., Sarma, K. V., et al. (2008). A Double Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of S-Loxin for Treatment of Osteoarthritis of the Knee. Arthritis Res. Ther. 10, R85. doi:10.1186/ar2461

Slenter, D. N., Kutmon, M., Hanspers, K., Buita, A., Windsor, J., Nunes, N., et al. (2018). WikiPathways: a Multifaceted Pathway Database Bridging Metabolomics to Other Omics Research. Nucleic Acids Res. 46, D661–D667. doi:10.1093/nar/gkx1064

Tausch, L., Henkel, A., Siemoneit, U., Poeckel, D., Kather, N., Franke, L., et al. (2009). Identification of Human Cathepsin G as a Functional Target of Boswellic Acids from the Anti-inflammatory Remedy Frankincense. J. Immunol. 183, 3433–3442. doi:10.4049/jimmunol.1830357

Tossetta, G., Fantone, S., Licini, C., Marzioni, D., and Mattioli-Belmonte, M. (2022). The Multi-faced Role of HtrA1 in the Development of Joint and Skeletal Disorders. Bone 157, 116350. doi:10.1016/j.bone.2022.116350

Wang, Y., Zhao, X., Lotz, M., Terkeltaub, R., and Liu-Bryan, R. (2015). Mitochondrial Biogenesis Is Impaired in Osteoarthritic Chondrocytes but Reversible via Peroxisome Proliferator-Activated Receptor γ Coactivator 1a. Arthritis Rheumatol. 67, 2141–2153. doi:10.1002/art.39182

Wang, Z., Jones, G., Winzenberg, T., Cai, G., Laslett, L. L., Atiken, D., et al. (2020). Effectiveness of Curcuma Longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis: A Randomized Trial. Ann. Intern. Med. 173, 861–869. doi:10.7326/M20-0990

Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., et al. (2021). clusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data. Innovation 2, 100141. doi:10.1016/j.innovation.2021.100141

Zeng, L., Yu, G., Hao, W., Yang, K., and Chen, H. (2021). The Efficacy and Safety of Curcuma Longa Extract and Curcumin Supplements on Osteoarthritis: a Systematic Review and Meta-Analysis. Biosci. Rep. 41. doi:10.1042/BSR20210817

Zhao, L., Li, H., Wang, Y., Zheng, A., Cao, L., and Liu, J. (2019). Autophagy Deficiency Leads to Impaired Antioxidant Defense via P62-Foxo1/3 Axis. Oxid. Med. Cell Longev. 2019, 2526314. doi:10.1155/2019/2526314

Conflict of Interest: YD is a Tilman SA employee. YH received consulting fees from Tilman SA.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Sanchez, Zappia, Lambert, Fougueune, Dierckxsen, Dubuc, Delcour, Gohot and Henrotin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.